Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. by Fouque, D. et al.
Nephrol Dial Transplant (2008) 23: 2902–2910
doi: 10.1093/ndt/gfn131
Advance Access publication 11 April 2008
Original Article
Use of a renal-specific oral supplement by haemodialysis patients with
low protein intake does not increase the need for phosphate binders
and may prevent a decline in nutritional status and quality of life
Denis Fouque1, Jane McKenzie2,∗, Rene´e de Mutsert3,∗, Raymond Azar4, Daniel Teta5, Mathias Plauth6,
Noel Cano7 and the Renilon Multicentre Trial Study Group
1Department of Nephrology, Hoˆpital Edouard Herriot, 69003 Lyon and Universite´ Lyon 1, INSERM U 870 Lyon, F-69003, France,
2Queen Margaret University, Edinburgh EH21 6UU, United Kingdom, 3Leiden University Medical Centre, PO Box 9600, 2300 RC
Leiden, The Netherlands, 4Service de Ne´phrologie, Hoˆpital de Dunkerque, F-59385, France, 5Service de Ne´phrologie et
d’Hypertension, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 17, CH 1005 Lausanne, Switzerland, 6Klinik fu¨r
Innere Medizin, Sta¨dtisches Klinikum, Auenweg 38, 06847 Dessau, Germany and 7CRNH Auvergne, Laboratoire de Nutrition
Humaine, BP 321, Clermont-Ferrand 63001 Cedex1, France
Abstract
Background. Protein-energy wasting is a frequent and
debilitating condition in maintenance dialysis. We ran-
domly tested if an energy-dense, phosphate-restricted,
renal-specific oral supplement could maintain adequate nu-
tritional intake and prevent malnutrition in maintenance
haemodialysis patients with insufficient intake.
Methods. Eighty-six patients were assigned to a standard
care (CTRL) group or were prescribed two 125-ml packs
of Renilon 7.5 R© daily for 3 months (SUPP). Dietary intake,
serum (S) albumin, prealbumin, protein nitrogen appear-
ance (nPNA), C-reactive protein, subjective global assess-
ment (SGA) and quality of life (QOL) were recorded at
baseline and after 3 months.
Results.While intention to treat analysis (ITT) did not re-
veal strong statistically significant changes in dietary intake
between groups, per protocol (PP) analysis showed that the
SUPP group increased protein (P < 0.01) and energy (P <
0.01) intakes. In contrast, protein and energy intakes further
deteriorated in the CTRL group (PP). Although there was
no difference in serum albumin and prealbumin changes
between groups, in the total population serum albumin and
prealbumin changes were positively associated with the in-
crement in protein intake (r = 0.29, P = 0.01 and r = 0.27,
P = 0.02, respectively). The SUPP group did not increase
phosphate intake, phosphataemia remained unaffected, and
the use of phosphate binders remained stable or decreased.
The SUPP group exhibited improved SGA and QOL
(P < 0.05).
Conclusion. This study shows that providing maintenance
haemodialysis patients with insufficient intake with a renal-
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specific oral supplement may prevent deterioration in nu-
tritional indices and QOL without increasing the need for
phosphate binders.
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Introduction
A significant number of individuals with chronic renal
failure, particularly those on maintenance haemodialysis
(MHD), have a poor nutritional status [1–6] and the im-
pact of this on patient health has been extensively doc-
umented [7–10]. Several studies have linked biochemical
and clinical indicators of poor nutritional status to an in-
creased risk of morbidity and mortality in MHD patients
[11–14]. In particular, low measurements of serum albu-
min [12,13,15–17], normalized protein nitrogen appear-
ance (nPNA) [15,18], body mass index (BMI) [12,16],
subjective global assessment (SGA) [16], serum prealbu-
min [19,20], serum creatinine [16,20], low protein [15]
and low energy intake [7] have been reported to corre-
late with an increased risk of mortality. Low serum albu-
min levels and reduced nPNA have also been associated
with increased time of hospitalization, indicating imme-
diate effects of poor nutritional status on patient health
[15,18,21,22].
Chronic malnutrition associated with maintenance
haemodialysis is primarily characterized by protein and
energy wasting. Several investigators have shown that
MHD patients consume less energy and protein than rec-
ommended [23,24]. Dietary restrictions can also make
the diet relatively unpalatable and attainment of adequate
protein intake quite challenging. In response to the evidence
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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indicating the importance of maintaining nutritional sta-
tus, guidelines provide recommendations for the intakes
of energy, protein and phosphate during maintenance dial-
ysis [25–27]. However, the impact of disease and the
haemodialytic therapy make attainment of recommended
intakes difficult [2].
Evidence indicating the potential value of nutritional
supplementation in preventing malnutrition and improv-
ing quality of life in MHD patients is limited and in-
consistent. While a recent systematic review showed that
supplemental nutrition improves nutritional intake and
serum albumin [28], insufficient data are available to
determine the effect of this on clinical outcomes. The
only randomized controlled trial comparing oral nutri-
tional supplementation versus routine care that could
be included in the meta-analysis provided supplemen-
tal nutrition to malnourished patients for just 1 month
[29].
The aim of this multicentre, randomized, open-label con-
trolled trial was to study the effect of an energy-dense renal-
specific oral nutritional supplement (Renilon 7.5 R©, N.V.
Nutricia, Zoetermeer, The Netherlands), on nutritional in-
take and status in haemodialysis patients over a 3-month
period. Renilon 7.5 has been developed in line with current
official European and American guidelines for dialysis pa-
tients [26,27]. It provides supplemental energy, protein and
vitamins to match the specific requirements of patients un-
dergoing dialysis: low in vitamin C, vitamin A, vitamin D,
phosphate and potassium to avoid excess intakes and com-
promise mineral status. The protein source used is a dem-
ineralized whey, which contains very lowminerals. In order
to optimize compliance and limit fluid intake, the supple-
ment that provides 2 kcal/mL is packaged into 125 mL tetra
packs. The supplement is available in two different flavours
(caramel and apricot) and has previously been shown to be
accepted by patients [30]. This study was designed to test
the hypothesis that daily supplementation with a specific
oral supplement could prevent or reduce deterioration of nu-
tritional status of mildly malnourished MHD patients. The
primary parameter for this trial was the nutritional status.
An improved nutritional status was defined as a significant
change from baseline after 3 months of supplementation
in any of the following parameters: nPNA, serum albumin,
pre-albumin, dry body weight and/or serum creatinine. The
effect of the nutritional supplement was compared to stan-
dard care, which in most cases does not include nutritional
support.
Methods
Patients
Mildly malnourished MHD patients at screening were se-
lected for inclusion in the study. A total of 88 patients
were recruited for the study from the 45 dialysis centres
belonging to the ‘Groupe de Recherche en Nutrition et
He´modialyse’ [1]. These patients were selected from a to-
tal of 2398 subjects, aged >18 years and on MHD for
at least 3 months. Mildly malnourished patients (defined
as both serum albumin <40 g/L and BMI <30 kg/m2)
were selected for inclusion if they had a low protein in-
take, indicated by an nPNA <1.0 g/kg/day, as this was
considered a high risk for developing malnutrition. Patients
with a C-reactive protein (CrP) level >20 mg/L at inclu-
sion were excluded. Other exclusion criteria were as fol-
lows: nutritional supplementation within the last 2 months
or the requirement for complete enteral nutrition, inade-
quate dialysis (Kt/V <1.2), peritoneal dialysis in the past
3 months or the use of any investigational drug. Base-
line characteristics of the patient population are described
in Table 1. The study protocol was approved by relevant
ethics review committees in each of the countries involved
(‘Comite´ Consultatif de Protection des Personnes dans la
Recherche Biome´dicale de Lyon A’, France; ‘Ethikkom-
mission, A¨rztekammer Sachsen-Anhalt’, Germany; ‘Com-
mission d’E´thique de la Recherche Clinique’, Lausanne,
Switzerland) and the study was conducted in accordance
with the ‘Declaration of Helsinki’. Informed and signed
consent was obtained from all study participants.
Study design
The study was a randomized, open-label controlled trial
in which the efficacy of an oral renal-specific nutritional
supplement was compared with standard care. Patients
were recruited from 18 centres in France, Germany and
Switzerland, and were stratified according to the study
centre and the presence of diabetes mellitus. Having ful-
filled the recruitment criteria, a baseline consultation was
scheduled, usuallywithin 3weeks, where baselinemeasures
were taken. Patients were then randomly assigned to either
the standard treatment group (CTRL) or the supplement
group (SUPP). Patients in the SUPP group were instructed
to take two 125 ml/day servings of a renal nutritional sup-
plement (Renilon 7.5 R©, N.V. Nutricia, Zoetermeer, The
Table 1. Baseline characteristics for patients receiving standard care (CTRL) or dietary supplementation (SUPP) of the intention to treat (ITT, all
patients) and per protocol (PP, patients that fulfilled the criteria for compliance, see the Methods section) groups of patients
ITT PP
CTRL (n = 40) SUPP (n = 46) CTRL (n = 37) SUPP (n = 29)
Number of males (%) 23 (50) 23 (43) 21 (57) 15 (52)
Age (years) 76.0 (38–90) 71.4 (21–90) 76.3 (38–90) 74.2 (41–90)
Years on dialysis (years) 3.4 (0.3–27.3) 2.7 (0.4–25.2) 3.3 (0.3–27.3) 2.8 (0.4–25.2)
Diabetes (n) 4 11 4 7
Data are expressed as median and range (lowest and highest value).
2904 D. Fouque et al.
Netherlands) for 3 months. Dietary advice was similarly
provided to both groups by the facility dietician, whereas no
nutritional supplementation was given to the CTRL group.
In the SUPP group, the prescribed nutritional supplemen-
tation provided an additional 500 kcal, 18.75 g protein, and
15 mg phosphorus per day. Throughout the 3-month study
period, patientswere followed on amonthly basis at baseline
(BL), Month 1 (M1), Month 2 (M2) andMonth 3 (M3). Di-
etary intake was assessed using a 2-day diet record at base-
line and after 3months, under the supervision of the dialysis
facility dietician, and included intakes on both a dialysis and
a non-dialysis day. All patients recorded their drug therapy
on a daily basis, and those in the SUPP group also recorded
their intake of the nutritional supplement alongside. Sub-
jects with an average supplement intake of<1250 ml/week
(10 packs) for 3 consecutive weeks were considered as non-
compliers. Product tolerance and any adverse events were
also recorded.
Blood samples were taken at baseline and after 3 months,
immediately prior to haemodialysis and were analysed by
the respective dialysis centre. Biochemical measurements
included serum albumin, prealbumin, creatinine, phos-
phate, calcium, haemoglobin, haematocrit, ferritin, gly-
cosylated haemoglobin (HbA1c) and C-reactive protein
(CRP). Normalized protein nitrogen appearance (nPNA)
and dialysis adequacy (Kt/V) were calculated according
to Garred et al. [31]. Serum lipids (triglycerides, choles-
terol, VLDL, LDL and HDL) and serum sodium, serum
potassium and bicarbonate were all measured at baseline
and after 3 months. In addition, measurements of body
mass index (BMI), dry body weight and mid-arm muscle
circumference (MAMC) were taken at baseline and af-
ter 3 months. Patients served as their own controls for
the calculations of the differences between baseline and
Month 3.
Nutritional statuswasmeasuredmonthlywith the 7-point
subjective global assessment (SGA), a modification of the
SGA originally described by Detsky et al. [32]. In this mod-
ification, objective and subjective information about recent
weight change, appetite and dietary intake, symptoms of
gastrointestinal distress and a visual assessment of body
composition are combined into a summary score of 1–7
[33,34]. The physician completed a SGA at each monthly
review. SGA was scored according to McCann [35] where
a score of 1–2 indicates severe risk of malnutrition, 3–5 in-
dicates a mild-to-moderate risk and 6–7 indicates no risk of
malnutrition. Quality of life scores were obtained at base-
line and after 3 months using the Medical Outcomes Study
(MOS) 36-item short form health survey (SF36) [36,37]
suitable for use in chronic renal failure [38].
Statistical analysis
Outcomes of this study were changes in nutritional and
biochemical parameters over the course of the 3-month
intervention period, as outlined in Table 3. The primary pa-
rameter for this trial was the nutritional status. An improved
nutritional status was defined as a significant change from
baseline after 3 months of supplementation in any of the
following parameters: nPNA, serum albumin, pre-albumin,
dry body weight and/or serum creatinine.
Sample size calculation was based on the albumin con-
centrations collected in a large database of HD patients in
France [1]. Taking into account a maximum variation of al-
bumin assay of 5%, it is possible to detect a mean difference
in albumin levels of 2.5 g/L or greater with a probability of
80% at the predetermined level of α = 0.05 with a sample
size of 42 patients per group. Data were analysed on an
intention to treat (ITT) and per protocol (PP) basis. The
ITT analysis included all recruited subjects providing base-
line measurements, whereas the PP analysis excluded all
subjects with protocol violations. Data were analysed using
ANOVA after confirming normality by Shapiro–Wilk tests
and equal variances by Levene tests. ANOVA included the
factors treatment (CTRL or SUPP), centre, and diabetes for
each time point and the differences from baseline values.
In addition, interactions were tested and where no interac-
tion was observed this was removed from the model. Data
that did not meet the criteria for ANOVAwere transformed,
where possible, to ensure normality or were analysed us-
ing the Mann–Whitney test. Quality of life data were also
analysed using the same ANOVA procedure. The outcomes
of SGA were compared between treatment groups using
Fisher’s exact test per visit and the change from baseline. As
proposed in clinical research, differences were considered
statistically significant when the P-value was <0.10. Data
are expressed as mean ± SD or as median (lowest–highest
value) for normally distributed or not normally distributed
data, as appropriate.
Results
Compliance
Seventeen patients were excluded in the PP analysis (SUPP
group) due to non-compliance with the required intake of
supplements (12 patients stopped taking the supplement
within the first week of the study, 3 took less than the
required amount for a period of 3 consecutive weeks and 2
consistently took less than the required amount throughout
the study period). Reasons for non-compliance included
dislike of the supplement and satiety. For the patients who
were able to comply with the supplementation (63%), the
average consumption was 93% of the two packs prescribed
daily. There were 15 subjects with diabetes in ITT (4 STD,
11 SUPP), and 11 were kept in the PP analysis (4 STD,
7 SUPP).
Dietary intake
Table 2 shows the differences in dietary intake from food
between baseline and after 3 months, as recorded by the
patients’ dietician. Dietary records of 8 patients were unin-
terpretable, while the dietary intakes of another 11 patients
were recorded outside the predetermined window of −21
or+7 days from baseline and−7 or+ 7 days fromMonth 3
measurements. These records were excluded from the ITT
as well as the PP analysis. Significant differences were ob-
served neither in the CTRL nor in the SUPP group in the
actual intakes of energy, protein, carbohydrate, fat, phos-
phate at baseline, or after 3 months, in the changes in intake
over the study period. The only exception was a significant
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Table 2. Changes from baseline in nutrient intakes from food alone, based on food report analysis, after 3 months of standard care (CTRL) or dietary
supplementation (SUPP) of the intention to treat (ITT, all patients) and per protocol (PP, compliant patients only) groups of patients
ITT PP
CTRL SUPP CTRL SUPP
Energy (kcal/day) −188.6 ± 334.2 −21.7 ± 427.9 −196.4 ± 344.9 −15.3 ± 435.7
n = 25 n = 34 n = 22 n = 23
Protein (g/day) −2.8 ± 20.2 1.5 ± 16.9 −4.6 ± 19.0 0.6 ± 16.7
n = 25 n = 34 n = 22 n = 23
Carbohydrate (g/day) −29.8 ± 51.3 −4.1 ± 61.0 −27.9 ± 54.2 −8.5 ± 59.1
n = 25 n = 34 n = 22 n = 23
Fat (g/day) −6.5 ± 17.3 −1.2 ± 20.8 −7.4 ± 17.3 1.8 ± 21.3∗
n = 25 n = 34 n = 22 n = 23
Phosphorus (mg/day) −80.2 (−404–1378) 39 (−545–563) −38.8 ± 283.4 36.5 ± 264.7
n = 23 n = 33 n = 20 n = 22
Calcium (mg/day) −0.5 (−570–950) −8 (−348–534) −51.4 ± 218.3 18.5 ± 204.4
n = 23 n = 33 n = 20 n = 22
∗Significant difference between groups (P = 0.03).
Data are expressed as mean ± SD, or as median and range (lowest and highest value), as appropriate.
Fig. 1. Total energy intake per kg body weight per day (mean ± SD) at
baseline (BL) and after 3 months (M3), and the difference in intake from
baseline. Energy intake at M3 was significantly greater in the SUPP group
(P < 0.001) and the difference in energy intake from baseline showed
a significant increase for the SUPP group (P = 0.03) after 3 months
(PP analysis).
increase in fat intake in the SUPP group in the PP analy-
sis (P = 0.03). When expressed per kg body weight, the
addition of the nutritional supplement to the diet increased
intake of energy and protein by 7.4 kcal/kg/day and 0.3 g
protein/kg/day, respectively, in the SUPP group, as shown
in Figures 1 and 2. Patients receiving the nutritional sup-
plement were consequently able to achieve intakes of 30.3
± 7.2 kcal/kg/day and 1.22 ± 0.4 g protein/kg/day (mean
± SD). Interestingly, phosphate intake did not differ be-
tween groups or from baseline throughout the study period,
as shown in Figure 3. As a result, mean intakes of phos-
phorus remained below the recommended upper limit of
1000 mg/day, despite the net increase in protein from the
nutritional supplement [26].
Biochemistry and anthropometry
Biochemical and anthropometric measurements at baseline
and the change from baseline at 3 months are presented in
Table 3. Changes after 3months of supplementation showed
consistent improvements in the SUPP group in compari-
Fig. 2. Total protein intake per kg body weight per day (mean ± SD)
at baseline (BL) and after 3 months (M3), and the difference in intake
from baseline. The difference in protein intake from baseline showed
a significant increase for the SUPP group (P < 0.01) after 3 months
(PP analysis).
Fig. 3. Total phosphate intake in mg per day (mean ± SD) at baseline
(BL) and after 3 months (M3), and the difference in intake from baseline.
Phosphorus intake did not differ between groups at baseline or 3 months.
Changes from BL were not significantly different between groups after
3 months (PP analysis).
son to the CTRL group for which all parameters, except
nPNA, deteriorated, although statistical significance was
not achieved. (Table 3).
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Table 3. Levels of nPNA, serum albumin, serum prealbumin, CRP, BMI and dry body weight measured at baseline (BL), and the change from baseline
after 3 months of standard care (CTRL) or dietary supplementation (SUPP) of the intention to treat (ITT, all patients) and per protocol (PP, compliant
patients only) populations
CTRL SUPP
BL Change from BL at M3 BL Change from BL at M3
ITT
nPNA (g/kg/day) 0.93 ± 0.2 0.03 (−0.5–0.6) 0.87 ± 0.3 0.07 (−0.5–1.87)
n = 35 n = 33 n = 46 n = 44
Serum albumin (g/L) 35.2 ± 6.4 −0.7 (−8.4–14.9) 35.2 ± 4.3 0 (−9.7–7.4)
n = 40 n = 38 n = 46 n = 46
Serum prealbumin (mg/L) 300 (110.0–638.0) 0 (−200.0–220.0) 286 (150.0–530.0) 15 (−160.0–110.0)
n = 40 n = 39 n = 46 n = 45
Serum CRP (mg/L) 6 (2.0–68.5) −0.4 (−67.8–136.0) 4.9 (0.5–91.0) 0 (−81.0–59.0)
n = 39 n = 39 n = 46 n = 44
BMI (kg/m2) 23.2 ± 3.9 −0.09 ± 0.5 23.6 ± 3.8 0.01 ± 0.9
n = 40 n = 40 n = 46 n = 45
Dry body weight (kg) 63.9 ± 14.8 −0.4 ± 1.5 62.4 ± 12.6 0.01 ± 2.2
n = 40 n = 40 n = 46 n = 46
PP
nPNA (g/kg/day) 0.91 ± 0.2 0.03 (−0.5–0.6) 0.87 ± 0.3 0.1 (−0.3–1.9)
n = 33 n = 31 n = 29 n = 27
Serum albumin (g/L) 35.0 ± 6.5 0 (−8.4–14.9) 34.8 ± 4.7 0 (−5.0–7.4)
n = 37 n = 35 n = 29 n = 29
Serum prealbumin (mg/L) 300 (110.0–638.0) 0 (−200.0–220.0) 282 (150.0–530.0) 18 (−100.0–110.0)
n = 37 n = 36 n = 29 n = 29
Serum CRP (mg/L) 5.6 (2.0–68.5) −0.5 (−67.8–136.0) 5 (0.5–21.0) 0 (−13.0–33.7)
n = 36 n = 36 n = 29 n = 29
BMI (kg/m2) 23.1 ± 3.7 −0.09 ± 0.5 23.5 ± 3.5 0.06 ± 0.7
n = 37 n = 37 n = 29 n = 28
Dry body weight (kg) 63.0 ± 13.7 −0.36 ± 1.5 61.7 ± 11.7 0.24 ± 1.9
n = 37 n = 37 n = 29 n = 29
No significant differences were observed between the CTRL and SUPP groups or over time within each group.
Data are expressed as mean ± SD, or as median and range (lowest–highest value), as appropriate.
Mean values for nPNA in the SUPP group after 1 and
2months (1.14± 0.4 and 1.07± 0.4, respectively) exceeded
1.0 g/kg/day. The analysis of nPNA at eachmonthly interval
also indicated significant differences between groups. The
change in nPNA from baseline was significantly greater for
the SUPP group in both the ITT (P = 0.03) and PP (P =
0.01) analyses after 1 month, and in the PP analysis (P =
0.03) after 2 months; however, no significant changes were
seen after 3 months.
The analysis of the correlation between the change in
nPNA and the change in serum albumin (Figure 4) or preal-
bumin (not shown) for both groups indicated a significant
positive relationship: an increase in nPNA corresponded
to a significant increase in serum albumin (P = 0.01)
and prealbumin (P = 0.02). This suggests that compliance
with the nutritional therapy should improve serum albumin
(Figure 4).
Dry body weight slightly increased after 3 months in the
SUPP group in comparison with the CTRL group in the PP
analysis (P = 0.07). No significant changes in MAMC
were observed between groups at baseline or following
the 3-month study period. Serum potassium, bicarbonate
and creatinine levels did not change significantly between
groups from baseline throughout the study period (data not
shown). There were no significant differences in serum lev-
els of CRP at baseline, nor there was a change from base-
line after 3 months significantly different between treat-
ments (Table 3). Similarly, no differences were observed in
Fig. 4. The relationship between the individual variation in protein in-
take (g/kg/day as assessed by nPNA) and serum albumin (g/l) during the
3-month period (ITT, n = 75; r = 0.293, P = 0.01), indicating that the
nutritional response was greater in patients with increased protein intake.
Of nine patients either the serum albumin or nPNA data were incomplete.
serum lipid levels (data not shown). Serum haemoglobin,
HbA1c, serum haematocrit and ferritin all remained sta-
ble throughout the study period, indicating no differences
between groups.
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Fig. 5. Median SGA at baseline (BL) and after 3 months (M3) for the
CTRL and SUPP groups; ∗ between group change from baseline, P <
0.05 (PP analysis). Solid lines indicate median results, with the block
representing the interquartile range and the whiskers indicating the results
range.
Serum phosphate levels did not differ from baseline or
between groups throughout the study period. At baseline,
phosphate binders were prescribed to 48 subjects (73%)
included in the PP analysis (27 STD, 21 SUPP). Through-
out the study period only eight patients (3 STD, 5 SUPP)
indicated a change in prescription, all of whom recorded a
decrease in phosphate binder use.
Subjective global assessment (SGA)
The results for the SGA for the ITT and PP groups are
presented in Figure 5. For the SUPP group, there was an
increase in median classification from 4, indicating a mild-
to-moderate risk, to 6, indicating no risk of malnutrition. In
the CTRL group, the median classification decreased, con-
sistently indicating a mild-to-moderate risk of malnutrition.
Quality of life
The SF36 Quality of Life questionnaire comprises eight
different parameters representing different components of
quality of life and their summaries (Table 4). A signifi-
cant difference between the changes in scores for the gen-
eral health and bodily pain components was identified in
the PP analysis (P = 0.01), indicating improvement in the
patients who effectively took the supplement. This differ-
ence was not seen in the ITT analysis, which included non-
compliant subjects. Overall, for the PP analysis, the SUPP
group showed consistent improvements in all individual and
summary component scores, except the score for vitality.
In contrast, the CTRL group showed deterioration in seven
of the eight individual component scores and also for the
physical component summary score. Results for the ITT
analysis showed a similar pattern of consistency.
Adverse events
Forty-three adverse events were reported 21 of which were
considered serious (stroke, myocardial infarction, fistula
Table 4. Mean changes from baseline in Quality of Life SF36 scores after
3 months of standard care (CTRL) or dietary supplementation (SUPP) of
the intention to treat (ITT, all patients) and per protocol (PP, compliant
patients only) groups of patients
Estimated marginal mean (EMM) ITT PP
CTRL SUPP CTRL SUPP
Physical functioning −2.49 2.47 −5.19 6.28
Physical role −14.92 −6.46 −13.02 2.50
Vitality −0.93 −5.57 −4.30 −2.02
Social functioning −0.14 0.53 0.75 7.46
Emotional role 4.49 6.89 −3.49 14.66
Mental health −0.74 2.73 −2.26 4.77
General health −2.64 3.30 −7.06 5.69∗
Bodily pain −15.05 −0.93 −20.54 2.83∗
Physical component summary −2.49 −0.69 −3.92 1.44
Mental component summary 3.89 2.75 0.839 2.94
∗Changes from baseline were significantly different between groups
(P = 0.01).
thrombosis, lower limb ischaemia and sepsis). None of the
serious adverse events were considered to be related to the
intake of the supplement, and there was no difference in
the distribution between treatment groups. Six non-serious
adverse events were identified to be potentially related to
the intake of Renilon 7.5 R©: hyperglycaemia (n = 1), vom-
iting (n = 2), mild abdominal pain (n = 2) and soft stools
(n = 1).
Discussion
This is the first open-label randomized controlled study
showing the effects of a renal-specific oral supplement in
MHD patients. The hypothesis was tested whether MHD
patients at risk of malnutrition would maintain an ade-
quate nutritional status by taking a daily oral supplement as
compared to patients receiving standard care. The results
showed that use of this oral supplement partially prevented
impairment of nutritional parameters and increased energy
and protein intake without increasing the use of phosphate
binders. Moreover, patients who complied with the supple-
mentation improved SGA and quality of life scores.
Based on biochemical indexes, the per protocol nutri-
tional response to supplementation was modest, with no
change in serum albumin and a non-significant increase
in prealbumin of 18 mg/L between the CTRL and SUPPL
groups. This could be explained by a number of factors.
Firstly, at the start of the study, the patients nutritional sta-
tus was only slightly impaired as compared to patients in-
volved in most previous studies in the field [28,39,40],
indicating that they were at risk of, rather than exhibiting,
overtmalnutrition. Secondly, therewas a large baseline vari-
ance in serum albumin, which may indicate some hetero-
geneity in the nutritional status of patients. The analysis of
biochemical parameters by the subsequent dialysis centres
might have introduced additional variations in the results,
although patients served as their own controls for the cal-
culations of the differences between baseline and Month 3.
Another potential drawback of using serum albumin as a
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marker of nutritional status is the influence of inflammation
on this marker [41]. Therefore, for this trial, patients were
selected with normal or moderately increased CRP levels
at the start of the trial. Moreover, the CRP levels hardly
changed during the 3-month period (median −0.5 and 0.0,
respectively) and no significant correlations were found
between changes in CRP and changes in serum albumin.
Whether these results apply to more inflamed patients can-
not be inferred from the present study and deserve further
research.
The albumin and prealbumin responses observed in this
study were limited in some patients (Figure 4), which might
be related to their higher values than those reported in pre-
vious nutritional studies [39,40,42,43], probably indicating
that these patients were in an early stage of malnourish-
ment, having been selected only on the basis of insufficient
dietary intakes. It is therefore conceivable that an albumin
response may have been greater in more malnourished pa-
tients [42,43].
The total amount of supplemental energy and protein
effectively taken from supplements in chronic disease is
generally lower than prescribed by physicians. In CKD,
most studies report supplemental energy intakes totalling
200–500 kcal/day [28,44]. It is important to note that IDPN,
which is administered just three times a week, cannot pro-
vide more energy/nutrients than oral supplements: in the
FineS study, the equivalent nutritional support from IDPN
was 420 kcal and 18 g protein per day [40]. In another IDPN
study over a 3-month period, patients actually received 30%
less than prescribed [43]. Oral essential or branched chain
amino acid supplements have been suggested to reduce
anorexia and/or improve appetite, as for instance shown by
Hiroshige et al. [45] or Eustace and coll. [46]. In another
short-term pilot study, Kalantar-Zadeh and colleagues re-
ported an improvement in serum albumin from 34.4 to
36.8 g/L (P < 0.01) in 20 malnourished MHD patients
taking a daily combination of supplements (Nepro R© +
OxepaTM) containing fish oil [47]. In a more recent trial,
Majchrzak et al. improved the anabolic effects of an oral
supplement by adding a short resistance exercise during
the haemodialysis session [48]. In the present study, there
was a clear trend for the CTRL group to spontaneously re-
duce energy and protein intakes, whereas the SUPP group
maintained their nutritional intake over the 3 months (Ta-
ble 2). An extended survey might have shown significant
worsening in the non-supplemented group over time.
Ensuring compliance is a key target for effective nutri-
tional therapy involving oral supplements. It is now well
documented that in most malnourished patients, even if
chronic inflammation occurs, increasing nutritional intake
will improve body composition [39,40,49]. In this study,
compliance was not as good as expected; 66% of patients
complied with the nutritional supplementation, achieving
an average additional intake of 7.4 kcal/kg/day and 0.3 g
protein/kg/day. However, this issue is well established in
MHD patients, compliance being close to 50% after 6 to
12 months of treatment in other studies [42,50]. Efforts
should be focused on barriers to compliance in this partic-
ular patient group. While compliance could be inadequate
due to (presumed) side effects (e.g. nausea and vomiting)
associated with taking oral supplements, this was the case
for only two patients in this study. Two other patients re-
fused to continue taking the supplement after the first day,
describing a feeling of fear of being overhydrated rather
than due to any direct problems with the supplement. In
these cases, accurately informing the patient, temporarily
decreasing the daily prescription or offering practical advice
on how to successfully incorporate the supplement into the
diet, seem all worthwhile efforts for successfully maintain-
ing this support. In fact, the supplement used in this study
is twice as concentrated (2 kcal/ml) as most supplements
available, and this may be of interest in patients who fear
of overhydration or who do not accept any modification of
their regular fluid intake.
The results observed in the ITT analysis were hampered
by the fact that non-compliant patientswere included,which
might have diluted the true efficacy of the supplement.
When analysed per protocol (also called ‘as treated’), the
positive effects, although non-significant, were slightly im-
proved (Table 3). Excluding any non-compliant patients
reflects the true efficacy of the supplement. Figure 4 also
confirms that the more the patients increased their intakes,
the greater was their albumin increment after 3 months.
Such a nutritional supplementation seems limited, but may
be adequate to prevent a patient entering the protein-energy-
wasting phase of CKD. Previous pilot studies in MHD have
associated this magnitude of intake with clear positive an-
abolic responses [28,44].
An additional benefit of the present supplement is the
very low phosphate content (15 mg/500 kcal), even though
it contains 7.5 g protein/100 ml. As a consequence, serum
phosphate did not increase in the SUPP group and it was
not necessary to increase phosphate binders, which is of
significant benefit to patients. In comparison, an equivalent
amount of protein from diet (e.g. one 100-g piece of red
meat) would have provided an additional 250 mg dietary
phosphate. Although controlling hyperphosphataemia by
reducing protein intake is not recommended anymore [51],
many patients still avoid high protein foods in order to
minimize the risk of hyperphosphataemia. Therefore, use of
a supplement with negligible phosphate content overcomes
this barrier.
Quality of life (QoL) is uncommonly reported in nutri-
tional studies in MHD patients, although a non-neglectable
issue [52,53]. Indeed,MHDpatients experience a decreased
quality of life and those who improve some of their quality
of life parameters are likely to eat better and/or comply with
nutritional support. Laws et al. [10] suggested an associa-
tion between severe malnutrition and poor quality of life,
and this was supported by Kalantar-Zadeh et al. [54] who
reported a correlation between serum albumin and SF36
score. Low intakes of protein and several micronutrients
correlated with poor quality of life scores in a study involv-
ing 60 MHD patients [55]. In the present study, all mean
SF36 parameters, except vitality, improved in the SUPP
group, and this increase was significant for general health
and bodily pain by PP analysis, whereas it was not signif-
icant in the control group (Table 4). This indicates a true
clinical improvement when patients successfully take their
supplement. The dietary supplement (Renilon 7.5) had a
beneficial effect on SGA and QoL scores, and this is of
clinical relevance to patients. Thus, this improvement in
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general status might have occurred at a very early stage of
malnutrition, before any impairment in body composition
and routine laboratory parameters could be detected.
In conclusion, this paper reports some beneficial effects
of a renal-specific oral nutritional support in MHD patients
who have a reduced nutritional intake and who are at risk
of emerging malnutrition. Compliance was similar to other
nutritional strategies and when patients complied, signif-
icant improvements in clinical status were observed. The
use of this energy-dense very low phosphate nutritional
supplement may prevent the development of malnutrition.
Whether these effects may be sustained over time will re-
quire long-term studies, but ultimately could lead to sig-
nificant cost benefits by reducing infectious complications
and hospitalization.
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